A special 13-article supplement to the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) examines the "Development and Future of Automated Insulin Delivery (AID) Systems.
New Endocrine Society statement with input from other organizations provides guidance for focusing on individual patient life circumstances that can affect their diabetes management.
The results found the use of oral treatments to be a noninferior alternative to insulin for preventing large-for-gestational age babies in women with gestational diabetes.
For people with T1D, severe hypoglycemia and impaired hypoglycemia awareness persisted despite the use of advanced technologies to monitor glucose and deliver insulin.